Apyx Medical Corp has a consensus price target of $8.88 based on the ratings of 5 analysts. The high is $17 issued by Lake Street on July 19, 2022. The low is $4.5 issued by Piper Sandler on August 11, 2023. The 3 most-recent analyst ratings were released by Stephens & Co., Piper Sandler, and Stephens & Co. on November 10, 2023, August 11, 2023, and July 14, 2023, respectively. With an average price target of $5.83 between Stephens & Co., Piper Sandler, and Stephens & Co., there's an implied 313.71% upside for Apyx Medical Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
11/10/2023 | Buy Now | 254.61% | Stephens & Co. | George Sellers | $8 → $5 | Maintains | Overweight | Get Alert |
08/11/2023 | Buy Now | 219.15% | Piper Sandler | Matt O'Brien | $4 → $4.5 | Maintains | Overweight | Get Alert |
07/14/2023 | Buy Now | 467.38% | Stephens & Co. | George Sellers | → $8 | Initiates | → Overweight | Get Alert |
06/15/2023 | Buy Now | 538.3% | Lake Street | Frank Takkinen | $6 → $9 | Maintains | Buy | Get Alert |
05/24/2023 | Buy Now | — | JMP Securities | David Turkaly | — | Reiterates | → Market Perform | Get Alert |
05/12/2023 | Buy Now | 325.53% | Lake Street | Frank Takkinen | $5 → $6 | Maintains | Buy | Get Alert |
12/08/2022 | Buy Now | 254.61% | Lake Street | Frank Takkinen | → $5 | Assumes | → Buy | Get Alert |
08/12/2022 | Buy Now | 751.06% | Piper Sandler | Matt O'Brien | $6 → $12 | Maintains | Overweight | Get Alert |
07/19/2022 | Buy Now | 1105.67% | Lake Street | Kyle Bauser | $14 → $17 | Maintains | Buy | Get Alert |
05/20/2022 | Buy Now | 751.06% | Lake Street | Kyle Bauser | → $12 | Initiates | → Buy | Get Alert |
08/13/2021 | Buy Now | 892.91% | JMP Securities | David Turkaly | — | Maintains | Market Outperform | Get Alert |
The latest price target for Apyx Medical (NASDAQ:APYX) was reported by Stephens & Co. on November 10, 2023. The analyst firm set a price target for $5.00 expecting APYX to rise to within 12 months (a possible 254.61% upside). 2 analyst firms have reported ratings in the last year.
The latest analyst rating for Apyx Medical (NASDAQ:APYX) was provided by Stephens & Co., and Apyx Medical maintained their overweight rating.
There is no last upgrade for Apyx Medical
There is no last downgrade for Apyx Medical.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apyx Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apyx Medical was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
While ratings are subjective and will change, the latest Apyx Medical (APYX) rating was a maintained with a price target of $8.00 to $5.00. The current price Apyx Medical (APYX) is trading at is $1.41, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.